Alnylam Pharmaceuticals Inc, Cambridge, Mass, says studies for its experimental therapy for the treatment of a respiratory disease, ALN-RSV01, show it is safe and well-tolerated.
The company conducted a double-blind, placebo controlled study with 88 adults. The subjects received ALN-RSV01 or placebo in a nasal form for five consecutive days. Complete study results will be presented at the International Symposium on Respiratory Viral Infections taking place Feb. 28-March 2 in Singapore.
